11 companies

Merck

Market Cap: US$283.1b

Operates as a healthcare company worldwide.

MRK

US$111.90

7D

-6.0%

1Y

35.2%

Illumina

Market Cap: US$19.4b

Provides sequencing- and array-based solutions for genetic and genomic analysis in the Americas, Europe, Greater China, the Asia Pacific, the Middle East, and Africa.

ILMN

US$127.88

7D

-4.9%

1Y

65.3%

Exelixis

Market Cap: US$11.7b

An oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States.

EXEL

US$44.94

7D

0.1%

1Y

20.1%

ACADIA Pharmaceuticals

Market Cap: US$3.8b

A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.

ACAD

US$21.96

7D

-0.9%

1Y

49.1%

ADMA Biologics

Market Cap: US$2.6b

A biopharmaceutical company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally.

ADMA

US$11.26

7D

2.3%

1Y

-48.5%

Aurinia Pharmaceuticals

Market Cap: US$2.1b

A biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan.

AUPH

US$15.98

7D

-0.4%

1Y

95.4%

Theravance Biopharma

Market Cap: US$839.8m

A biopharmaceutical company, develops and commercializes medicines in the United States.

TBPH

US$16.46

7D

-4.5%

1Y

68.8%

CorMedix

Market Cap: US$582.7m

A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.

CRMD

US$7.42

7D

0.4%

1Y

-18.5%

Abeona Therapeutics

Market Cap: US$314.0m

A commercial-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases in the United States.

ABEO

US$5.39

7D

-2.0%

1Y

1.1%

Compugen

Market Cap: US$276.1m

A clinical-stage therapeutic discovery and development company, engages in the research, development, and commercialization of therapeutics and product candidates in Israel, the United States, and Europe.

CGEN

US$3.10

7D

9.9%

1Y

109.5%

Oramed Pharmaceuticals

Market Cap: US$155.3m

Engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins.

ORMP

US$3.85

7D

-0.8%

1Y

65.2%